Spontaneous canine gliomas: Overexpression of EGFR, PDGFRα and IGFBP2 demonstrated by tissue microarray immunophenotyping

Robert Higgins, Peter J Dickinson, Richard A Lecouteur, Andrew W. Bollen, Huamin Wang, Hua Wang, Linda J. Corely, Lynnette M. Moore, Wei Zang, Gregory N. Fuller

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Fifty-seven spontaneous canine gliomas were histologically classified and graded using the latest World Health Organization (WHO 2007) criteria for classification of human gliomas. A total of 19 canine astrocytomas were classified as follows: grade IV (GBM) n = 7; grade III n = 5; and grade II, n = 7. Thirty-eight oligodendrogliomas were classified as either grade III (anaplastic) n = 35 or low grade II n = 3. Tissue microarray (TMA) immunohistochemistry was used to evaluate tumor expression of EGFR, PDGFRa and IGFBP2, three key molecules of known pathophysiological importance in human gliomas. Findings were correlated with tumor classification and grade. Increased EGFR expression was demonstrated in 57% of GBMs, 40% of grade III and 28% of grade II astrocytomas. EGFR expression occurred in only 3% of grade III oligodendrogliomas. Increased expression of PDGFRα was demonstrated in 43% of GBMs, 20% of grade III, and 14% of grade II astrocytomas. In the oligodendroglioma series, 94% of grade III tumors overexpressed PDGFRα. IGFBP2 expression was detected in 71, 60 and 28% of GBMs, grade III and grade II astrocytomas respectively. IGFBP2 expression occurred in 48% of anaplastic and in 33% of low grade oligodendrogliomas. Expression of EGFR, PDGFRα or IGFBP2 was not detected in normal canine CNS control TMA cores. The incidence of overexpression of EGFR, PDGFRα and IGFBP2 in these canine gliomas closely parallels that in human tumors of similar type and grade. These findings support a role for the spontaneous canine glioma model in directed pathway-targeting therapeutic studies.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalJournal of Neuro-Oncology
Volume98
Issue number1
DOIs
StatePublished - May 2010

Fingerprint

Immunophenotyping
Oligodendroglioma
Glioma
Astrocytoma
Canidae
Neoplasms
Immunohistochemistry
Incidence

Keywords

  • Canine
  • EGFR
  • Glioma
  • IGFBP2
  • Immunohistochemistry
  • PDGFRα
  • Tissue microarray

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Spontaneous canine gliomas : Overexpression of EGFR, PDGFRα and IGFBP2 demonstrated by tissue microarray immunophenotyping. / Higgins, Robert; Dickinson, Peter J; Lecouteur, Richard A; Bollen, Andrew W.; Wang, Huamin; Wang, Hua; Corely, Linda J.; Moore, Lynnette M.; Zang, Wei; Fuller, Gregory N.

In: Journal of Neuro-Oncology, Vol. 98, No. 1, 05.2010, p. 49-55.

Research output: Contribution to journalArticle

Higgins, Robert ; Dickinson, Peter J ; Lecouteur, Richard A ; Bollen, Andrew W. ; Wang, Huamin ; Wang, Hua ; Corely, Linda J. ; Moore, Lynnette M. ; Zang, Wei ; Fuller, Gregory N. / Spontaneous canine gliomas : Overexpression of EGFR, PDGFRα and IGFBP2 demonstrated by tissue microarray immunophenotyping. In: Journal of Neuro-Oncology. 2010 ; Vol. 98, No. 1. pp. 49-55.
@article{98bb51ddb17b4836afddf55311a936ea,
title = "Spontaneous canine gliomas: Overexpression of EGFR, PDGFRα and IGFBP2 demonstrated by tissue microarray immunophenotyping",
abstract = "Fifty-seven spontaneous canine gliomas were histologically classified and graded using the latest World Health Organization (WHO 2007) criteria for classification of human gliomas. A total of 19 canine astrocytomas were classified as follows: grade IV (GBM) n = 7; grade III n = 5; and grade II, n = 7. Thirty-eight oligodendrogliomas were classified as either grade III (anaplastic) n = 35 or low grade II n = 3. Tissue microarray (TMA) immunohistochemistry was used to evaluate tumor expression of EGFR, PDGFRa and IGFBP2, three key molecules of known pathophysiological importance in human gliomas. Findings were correlated with tumor classification and grade. Increased EGFR expression was demonstrated in 57{\%} of GBMs, 40{\%} of grade III and 28{\%} of grade II astrocytomas. EGFR expression occurred in only 3{\%} of grade III oligodendrogliomas. Increased expression of PDGFRα was demonstrated in 43{\%} of GBMs, 20{\%} of grade III, and 14{\%} of grade II astrocytomas. In the oligodendroglioma series, 94{\%} of grade III tumors overexpressed PDGFRα. IGFBP2 expression was detected in 71, 60 and 28{\%} of GBMs, grade III and grade II astrocytomas respectively. IGFBP2 expression occurred in 48{\%} of anaplastic and in 33{\%} of low grade oligodendrogliomas. Expression of EGFR, PDGFRα or IGFBP2 was not detected in normal canine CNS control TMA cores. The incidence of overexpression of EGFR, PDGFRα and IGFBP2 in these canine gliomas closely parallels that in human tumors of similar type and grade. These findings support a role for the spontaneous canine glioma model in directed pathway-targeting therapeutic studies.",
keywords = "Canine, EGFR, Glioma, IGFBP2, Immunohistochemistry, PDGFRα, Tissue microarray",
author = "Robert Higgins and Dickinson, {Peter J} and Lecouteur, {Richard A} and Bollen, {Andrew W.} and Huamin Wang and Hua Wang and Corely, {Linda J.} and Moore, {Lynnette M.} and Wei Zang and Fuller, {Gregory N.}",
year = "2010",
month = "5",
doi = "10.1007/s11060-009-0072-5",
language = "English (US)",
volume = "98",
pages = "49--55",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Spontaneous canine gliomas

T2 - Overexpression of EGFR, PDGFRα and IGFBP2 demonstrated by tissue microarray immunophenotyping

AU - Higgins, Robert

AU - Dickinson, Peter J

AU - Lecouteur, Richard A

AU - Bollen, Andrew W.

AU - Wang, Huamin

AU - Wang, Hua

AU - Corely, Linda J.

AU - Moore, Lynnette M.

AU - Zang, Wei

AU - Fuller, Gregory N.

PY - 2010/5

Y1 - 2010/5

N2 - Fifty-seven spontaneous canine gliomas were histologically classified and graded using the latest World Health Organization (WHO 2007) criteria for classification of human gliomas. A total of 19 canine astrocytomas were classified as follows: grade IV (GBM) n = 7; grade III n = 5; and grade II, n = 7. Thirty-eight oligodendrogliomas were classified as either grade III (anaplastic) n = 35 or low grade II n = 3. Tissue microarray (TMA) immunohistochemistry was used to evaluate tumor expression of EGFR, PDGFRa and IGFBP2, three key molecules of known pathophysiological importance in human gliomas. Findings were correlated with tumor classification and grade. Increased EGFR expression was demonstrated in 57% of GBMs, 40% of grade III and 28% of grade II astrocytomas. EGFR expression occurred in only 3% of grade III oligodendrogliomas. Increased expression of PDGFRα was demonstrated in 43% of GBMs, 20% of grade III, and 14% of grade II astrocytomas. In the oligodendroglioma series, 94% of grade III tumors overexpressed PDGFRα. IGFBP2 expression was detected in 71, 60 and 28% of GBMs, grade III and grade II astrocytomas respectively. IGFBP2 expression occurred in 48% of anaplastic and in 33% of low grade oligodendrogliomas. Expression of EGFR, PDGFRα or IGFBP2 was not detected in normal canine CNS control TMA cores. The incidence of overexpression of EGFR, PDGFRα and IGFBP2 in these canine gliomas closely parallels that in human tumors of similar type and grade. These findings support a role for the spontaneous canine glioma model in directed pathway-targeting therapeutic studies.

AB - Fifty-seven spontaneous canine gliomas were histologically classified and graded using the latest World Health Organization (WHO 2007) criteria for classification of human gliomas. A total of 19 canine astrocytomas were classified as follows: grade IV (GBM) n = 7; grade III n = 5; and grade II, n = 7. Thirty-eight oligodendrogliomas were classified as either grade III (anaplastic) n = 35 or low grade II n = 3. Tissue microarray (TMA) immunohistochemistry was used to evaluate tumor expression of EGFR, PDGFRa and IGFBP2, three key molecules of known pathophysiological importance in human gliomas. Findings were correlated with tumor classification and grade. Increased EGFR expression was demonstrated in 57% of GBMs, 40% of grade III and 28% of grade II astrocytomas. EGFR expression occurred in only 3% of grade III oligodendrogliomas. Increased expression of PDGFRα was demonstrated in 43% of GBMs, 20% of grade III, and 14% of grade II astrocytomas. In the oligodendroglioma series, 94% of grade III tumors overexpressed PDGFRα. IGFBP2 expression was detected in 71, 60 and 28% of GBMs, grade III and grade II astrocytomas respectively. IGFBP2 expression occurred in 48% of anaplastic and in 33% of low grade oligodendrogliomas. Expression of EGFR, PDGFRα or IGFBP2 was not detected in normal canine CNS control TMA cores. The incidence of overexpression of EGFR, PDGFRα and IGFBP2 in these canine gliomas closely parallels that in human tumors of similar type and grade. These findings support a role for the spontaneous canine glioma model in directed pathway-targeting therapeutic studies.

KW - Canine

KW - EGFR

KW - Glioma

KW - IGFBP2

KW - Immunohistochemistry

KW - PDGFRα

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=77953616455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953616455&partnerID=8YFLogxK

U2 - 10.1007/s11060-009-0072-5

DO - 10.1007/s11060-009-0072-5

M3 - Article

C2 - 19967449

AN - SCOPUS:77953616455

VL - 98

SP - 49

EP - 55

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -